Research Paper Volume 12, Issue 19 pp 19316—19324
SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients
Predicting of ICB response based on SYNE1 mutation and biomarker evaluation. (A) Violin plot showing the differential TIDE between the mt and wt groups. (B) Evaluation of SYNE1 as a biomarker compared with existing biomarkers. (C) Multivariate analysis of SYNE1 and existing biomarkers using the COX proportional hazards model.